Abstract

Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites. We previously showed that a single dose of IPSE (Interleukin-4-inducing principle from Schistosoma eggs), a schistosome-derived host modulatory protein, can ameliorate ifosfamide-related cystitis; however, the mechanisms underlying this urotoxicity and its prevention are not fully understood. To provide insights into IPSE’s protective mechanism, we undertook transcriptional profiling of bladders from ifosfamide-treated mice, with or without pretreatment with IPSE or IPSE-NLS (a mutant of IPSE lacking nuclear localization sequence). Ifosfamide treatment upregulated a range of proinflammatory genes. The IL-1β-TNFα-IL-6 proinflammatory cascade via NFκB and STAT3 pathways was identified as the key driver of inflammation. The NRF2-mediated oxidative stress response pathway, which regulates heme homoeostasis and expression of antioxidant enzymes, was highly activated. Anti-inflammatory cascades, namely Wnt, Hedgehog and PPAR pathways, were downregulated. IPSE drove significant downregulation of major proinflammatory pathways including the IL-1β-TNFα-IL-6 pathways, interferon signaling, and reduction in oxidative stress. IPSE-NLS reduced inflammation but not oxidative stress. Taken together, we have identified signatures of acute-phase inflammation and oxidative stress in ifosfamide-injured bladder, which are reversed by pretreatment with IPSE. This work revealed several pathways that could be therapeutically targeted to prevent ifosfamide-induced hemorrhagic cystitis.

Details

Title
IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways
Author
Mbanefo, Evaristus C 1 ; Le Loc 2 ; Zee, Rebecca 1 ; Banskota Nirad 2 ; Ishida Kenji 2 ; Pennington, Luke F 3 ; Odegaard, Justin I 4 ; Jardetzky, Theodore S 3 ; Alouffi Abdulaziz 5 ; Falcone, Franco H 6   VIAFID ORCID Logo  ; Hsieh, Michael H 7   VIAFID ORCID Logo 

 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9); Children’s National Medical Center, Division of Urology, Washington, USA (GRID:grid.239560.b) (ISNI:0000 0004 0482 1586) 
 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9) 
 Stanford University School of Medicine, Department of Structural Biology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956) 
 Guardant Health, Redwood City, USA (GRID:grid.168010.e) 
 King Abdulaziz City for Science & Technology (KACST), Life Science & Environment Sector, Riyadh, Saudi Arabia (GRID:grid.452562.2) (ISNI:0000 0000 8808 6435) 
 School of Pharmacy, University of Nottingham, Division of Molecular Therapeutics and Formulation, Nottingham, UK (GRID:grid.4563.4) (ISNI:0000 0004 1936 8868) 
 Biomedical Research Institute, Bladder Immunology Group, Rockville, USA (GRID:grid.418352.9); Children’s National Medical Center, Division of Urology, Washington, USA (GRID:grid.239560.b) (ISNI:0000 0004 0482 1586); The George Washington University, Department of Urology, Washington, USA (GRID:grid.253615.6) (ISNI:0000 0004 1936 9510) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2176710279
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.